Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12
May 14, 2015 16:15 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., May 14, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for the...
Arno Therapeutics Announces Data Validating Continued Onapristone and Companion Diagnostic Development at ASCO Annual Meeting 2015
May 13, 2015 17:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., May 13, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer and...
Arno Therapeutics Receives USPTO Notice of Allowance for Two Important Patents Covering Lead Compound Onapristone
May 07, 2015 08:30 ET
|
Arno Therapeutics Inc.
Patents to Cover Methods of Use and Diagnostic Methods for Identifying Anti-Progestin Sensitive Tumors
Issuance Will Ensure Comprehensive Protection of Onapristone
FLEMINGTON, N.J. , May 7,...
Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases
April 30, 2015 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., April 30, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for the...
Arno Therapeutics to Present Three Posters Supporting Onapristone Development at ASCO Annual Meeting 2015
April 29, 2015 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., April 29, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer...
Arno Therapeutics to Present Promising Data From Phase I Trial of Onapristone at AACR Annual Meeting 2015
April 21, 2015 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., April 21, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer...
Arno Therapeutics Announces Three Poster Presentations at Upcoming AACR Annual Meeting 2015
April 13, 2015 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., April 13, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of therapeutics for cancer...
Arno Therapeutics Reports Fourth Quarter 2014 Financial and Business Update
March 31, 2015 16:38 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., March 31, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development therapeutics for cancer and other life...
New Data Supporting Arno Therapeutics' HDAC Inhibitor AR-42 Published in The Journal of Urology
March 24, 2015 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., March 24, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics,...
Arno Therapeutics to Present at 11th Annual Noble Equity Conference
January 08, 2015 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Jan. 8, 2015 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics, today...